Biotinylated-chemokine antibody complexes

Details Biotinylated-chemokine antibody complexes Biotinylated-chemokine antibody complexes

2005-03-22

2005-03-22

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C514S002600, C530S391700, C530S807000, C530S389800, C530S387300, C530S388250, C548S303700, C549S069000

Reexamination Certificate

active

06869606

ABSTRACT:
Biotinylated pharmacologically active agents and complexes containing same are disclosed. In particular, biotinylated-chemokines are described. The complexes further include an anti-biotin antibody that selectively binds to biotin. The complex can be dissociated by contact with free biotin. The complexes are particularly useful for enhancing an immune response to tumor cells and virus-infected cells, in vivo or in vitro.

REFERENCES:
patent: 5428130 (1995-06-01), Capon et al.
patent: 5518882 (1996-05-01), Lund et al.
patent: 5607659 (1997-03-01), Gustavson et al.
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5700444 (1997-12-01), Zamora et al.
patent: 5716594 (1998-02-01), Elmaleh et al.
patent: 5759515 (1998-06-01), Rhodes et al.
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5807879 (1998-09-01), Rosebrough
patent: 5824782 (1998-10-01), Holzer et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5834419 (1998-11-01), McFadden et al.
patent: 5929066 (1999-07-01), McCarty
patent: 6214450 (2001-04-01), Wickert et al.
patent: 6303325 (2001-10-01), Mehta et al.
patent: 6638508 (2003-10-01), Schechter et al.
patent: 0 217 577 (1987-04-01), None
patent: 337746 (1989-10-01), None
patent: 0 460 569 (1991-12-01), None
patent: WO 9640251 (1996-12-01), None
patent: WO 9833914 (1998-08-01), None
patent: WO 9838212 (1998-09-01), None
patent: WO 0012554 (2000-03-01), None
patent: WO 0042071 (2000-07-01), None
Abstract of Tromholt et al (Journal of Nuclear Medcine, 1991, vol. 32, pp. 2318-2321).*
Batra, Raj K., “Receptor-Mediated Gene Delivery Employing Lectin-Binding Specificity,” Gene Therapy, 1:4, pp. 255-260 (1994) (Abstract).
Hechtman, D.H. et al., “Inhibitor of Polymorphonuclear Leukoctye Accumulation at Sites of Acute Inflammation,”The Journal of immunology, vol. 147, (1991), pp. 883-892.
Mock, D.M. et al., “Distribution of Biotin in Human Plasma: Most of the Biotin Is Not Bound to Protein,”Am. J. Clin. Nutr., (1992) vol. 56, No. 2., pp. 427-432—Abstract Only.
Dale, G.L. et al., “Antibodies Against Biotinylated Proteins Are Present in Normal Human Serum,”J. Lab. Clin. Med. (1994), vol. 123, No. 3, pp. 365-371—Abstract Only.
Bagei, H. et al., Monoclonal Anti-Biotin Antibodies Simulate Avidin in the Recognition of Biotin,FEBS 12391, vol. 322, No. 1 (1993), pp. 47-50.
Challita-Eid, P.M. et al., “A Rantes-Antibody Rusion Protein Retains Antigen Specificity and Chemokine Function,”The Journal of Immunology, 1998, vol. 161, pp. 3729-3736.
Lussow, A.R. et al., “Targeting of Antihapten Antibodies to Activated T Cells Via an II-2-Hapten Conjugate Prolongs Cardiac Graft Survival,”Transplantation, (1996), vol. 62, pp. 1703-1708.
Gimbrone, Jr., M.A. et al., “Endothelial Interleukin-8: A Novel Inhibitor of Leukocyte-Endothelial Interactions,”Science, vol. 246, (1989), pp. 1601-1603.

Affiliated with

Also associated with

Rating

Biotinylated-chemokine antibody complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biotinylated-chemokine antibody complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotinylated-chemokine antibody complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3409327